title: Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal".
authors.affiliation: Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA.
authors.forename: Odette
authors.initials: O
authors.lastname: Reifsnider
authors.affiliation: Janssen-Cilag Limited, High Wycombe, Buckinghamshire, UK.
authors.forename: Fiona
authors.initials: F
authors.lastname: Hall
authors.affiliation: Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA. sonja.sorensen@evidera.com.
authors.forename: Sonja
authors.initials: S
authors.lastname: Sorensen
authors.affiliation: Evidera, Montreal, QC, Canada.
authors.forename: Irina
authors.initials: I
authors.lastname: Proskorovsky
authors.affiliation: Janssen-Cilag Limited, High Wycombe, Buckinghamshire, UK.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Girod
authors.affiliation: Janssen-Cilag Limited, High Wycombe, Buckinghamshire, UK.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Lee
mesh_terms: D000069501:Abiraterone Acetate; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D011241:Prednisone; D064129:Prostatic Neoplasms, Castration-Resistant
chemical_list: D000069501:Abiraterone Acetate; D011241:Prednisone